N-n-Butyl Haloperidol Iodide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564794

CAS#: NONE

Description: N-n-Butyl haloperidol iodide is an inhibitor of autophagy which protects cardiomyocytes against hypoxia and reoxygenation injury.

Chemical Structure

img
N-n-Butyl Haloperidol Iodide
CAS# NONE
Instruction

Theoretical Analysis

MedKoo Cat#: 564794
Name: N-n-Butyl Haloperidol Iodide
CAS#: NONE
Chemical Formula: C25H32ClFINO2
Exact Mass: 0.00
Molecular Weight: 559.890
Elemental Analysis: C, 53.63; H, 5.76; Cl, 6.33; F, 3.39; I, 22.67; N, 2.50; O, 5.72

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: N-n-Butyl haloperidol iodide

IUPAC/Chemical Name: 1-Butyl-4-(4-chloro-phenyl)-1-[4-(4-fluoro-phenyl)-4-oxo-butyl]-4-hydroxy-piperidinium iodide

InChi Key: JZOLZUFLPKVJDH-UHFFFAOYSA-M

InChi Code: InChI=1S/C25H32ClFNO2.HI/c1-2-3-16-28(17-4-5-24(29)20-6-12-23(27)13-7-20)18-14-25(30,15-19-28)21-8-10-22(26)11-9-21;/h6-13,30H,2-5,14-19H2,1H3;1H/q+1;/p-1

SMILES Code: OC1(C2=CC=C(Cl)C=C2)CC[N+](CCCC(C3=CC=C(F)C=C3)=O)(CCCC)CC1.[I-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 559.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lu B, Wang B, Zhong S, Zhang Y, Gao F, Chen Y, Zheng F, Shi G. N-n-butyl haloperidol iodide ameliorates hypoxia/reoxygenation injury through modulating the LKB1/AMPK/ROS pathway in cardiac microvascular endothelial cells. Oncotarget. 2016 Jun 7;7(23):34800-10. doi: 10.18632/oncotarget.9186. PubMed PMID: 27166184; PubMed Central PMCID: PMC5085190.

2: Wang B, Zhong S, Zheng F, Zhang Y, Gao F, Chen Y, Lu B, Xu H, Shi G. N-n-butyl haloperidol iodide protects cardiomyocytes against hypoxia/reoxygenation injury by inhibiting autophagy. Oncotarget. 2015 Sep 22;6(28):24709-21. doi: 10.18632/oncotarget.5077. PubMed PMID: 26359352; PubMed Central PMCID: PMC4694790.

3: Zhang Y, Liao H, Zhong S, Gao F, Chen Y, Huang Z, Lu S, Sun T, Wang B, Li W, Xu H, Zheng F, Shi G. Effect of N-n-butyl haloperidol iodide on ROS/JNK/Egr-1 signaling in H9c2 cells after hypoxia/reoxygenation. Sci Rep. 2015 Jul 2;5:11809. doi: 10.1038/srep11809. PubMed PMID: 26134032; PubMed Central PMCID: PMC4488875.

4: Huang YP, Gao FF, Wang B, Zheng FC, Zhang YM, Chen YC, Huang ZQ, Zheng YS, Zhong SP, Shi GG. N-n-butyl haloperidol iodide inhibits H2O2-induced Na+/Ca2+-exchanger activation via the Na+/H+ exchanger in rat ventricular myocytes. Drug Des Devel Ther. 2014 Sep 9;8:1257-67. doi: 10.2147/DDDT.S63163. eCollection 2014. PubMed PMID: 25246767; PubMed Central PMCID: PMC4166912.

5: Zhang Y, Chen G, Zhong S, Zheng F, Gao F, Chen Y, Huang Z, Cai W, Li W, Liu X, Zheng Y, Xu H, Shi G. N-n-butyl haloperidol iodide ameliorates cardiomyocytes hypoxia/reoxygenation injury by extracellular calcium-dependent and -independent mechanisms. Oxid Med Cell Longev. 2013;2013:912310. doi: 10.1155/2013/912310. Epub 2013 Nov 12. PubMed PMID: 24392181; PubMed Central PMCID: PMC3857550.